New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

Meiji Seika Pharma establishes local subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan: Tokyo Friday, December 27, 2024, 13:00 Hrs [IST] Meiji Seika Pharma Co., Ltd., a pha ...

Patent for methods of use of topical DNase enzymes in the eye covers L304, Neutrolis’ proprietary therapy in development for ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

This phase can last months, requiring various protective measures to prevent complications. Graft-versus-host disease remains ...

BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr ...

US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older: Melbourne, Australia Monday, December 23, 2024 ...

Meiji Seika Pharma announced the establishment of a local subsidiary, "Taiwan Meiji Pharma Co., Ltd." (Headquarters: Taipei ...

Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at ...

Bone marrow transplants, long a mainstay of blood cancer treatments, are becoming less common in favor of options like CAR-T ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...